Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 133 results for vitamin

  1. Single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity (IPG569)

    Evidence-based recommendations on single-anastomosis duodeno-ileal bypass with sleeve gastrectomy for treating morbid obesity. This involves reducing the size of the stomach and small intestine to reduce the amount of food absorbed.

    Interventional procedures guidance
    Published
    23 November 2016
    View recommendations

    Sections for IPG569

  2. Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (TA287)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and for preventing a further deep vein thrombosis or pulmonary embolism in adults.

    Technology appraisal guidance
    Published
    26 June 2013
    View recommendations

    Sections for TA287

  3. Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

    Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.

    Technology appraisal guidance
    Published
    23 January 2008
    View recommendations

    Sections for TA135

  4. COVID-19 rapid evidence summary: vitamin D for COVID-19 (ES28)

    This evidence summary has been updated and replaced by the COVID-19 rapid guideline on vitamin D (NG187).

    Evidence summary: COVID-19 rapid summary
    Published
    29 June 2020

  5. Needle fasciotomy for Dupuytren's contracture (IPG43)

    Evidence-based recommendations on needle fasciotomy for Dupuytren's contracture. This involves cutting one or more fibrous bands using a blade or a bevel of a needle.

    Interventional procedures guidance
    Published
    25 February 2004
    View recommendations

    Sections for IPG43

  6. Age-related macular degeneration (NG82)

    This guideline covers diagnosing and managing age-related macular degeneration (AMD) in adults. It aims to improve the speed at which people are diagnosed and treated to prevent loss of sight.

    NICE guideline
    Published
    23 January 2018
    View recommendations

    Sections for NG82

  7. Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)

    Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.

    Highly specialised technologies guidance
    Last updated
    8 April 2025
    View recommendations

    Sections for HST8

  8. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

    Evidence summary
    Published
    28 March 2017

  9. What types of information provision, including mass-media campaigns, are effective and cost effective in preventing skin cancer in the UK? What factors influence effectiveness and cost effectiveness? •Does effectiveness and cost effectiveness vary for different population groups? (Groups could be defined by gender, age, race/ethnicity, socioeconomic status or other characteristics such as lifestyle and at-risk behaviours.) • What impact do they have on knowledge, attitudes, awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors that aid or hinder the success of these interventions or campaigns, including for different population groups? In particular, how does changing attitudes to sunbathing and tanning – and perceptions of the risk of skin cancer –influence success? Do attitudes vary for different population groups?

    awareness and behaviour, including any impact on physical activity levels and vitamin D-related outcomes? • What are the key factors...

    Research recommendation
    Published
    9 June 2015

  10. What is the effectiveness and safety of standard-dose compared with intermediate-dose pharmacological venous thromboembolism (VTE) prophylaxis for people with COVID-19, with or without additional risk factors for VTE?

    direct-acting anticoagulant• vitamin K antagonists C: standard-dose:• LMWH UFH• fondaparinux sodium• direct-acting anticoagulants...

    Research recommendation
    Published
    10 August 2021

  11. What is the most clinical and cost-effective strategy, as identified by a consensus survey, for the perioperative management of anticoagulation treatment in people taking a vitamin K antagonist with a target international normalised ratio (INR) of more than 3 who need bridging therapy?

    perioperative management of anticoagulation treatment in people taking a vitamin K antagonist with a target international normalised...

    Research recommendation
    Published
    26 October 2020

  12. Neonatal parenteral nutrition (QS205)

    This quality standard covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date, and babies born at term, up to 28 days after their birth. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    22 March 2022
    View quality statements

    Sections for QS205

  13. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing a pulmonary embolism (PE) or another deep vein thrombosis in adults.

    Technology appraisal guidance
    Published
    25 July 2012
    View recommendations

    Sections for TA261

  14. Stable angina: management (CG126)

    This guideline covers managing stable angina in people aged 18 and over. It outlines the importance of addressing the person’s concerns about stable angina and the roles of medical therapy and revascularisation.

    Clinical guideline
    Last updated
    25 August 2016
    View recommendations

    Sections for CG126

  15. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

    NICE guideline
    Published
    29 October 2021
    View recommendations

    Sections for NG206